The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...

Platelet spreading and clot contraction are controlled by different pathways. This discovery leads to safer treatments for ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

Based on the information disclosed about Lillard's issue, it is not believed to be as serious as Bosh's. Here is a look at ...

Until recently, researchers believed that platelet spreading and clot contraction were controlled by the same pathway. However a recent study from Thomas Jefferson University researchers challenges ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Deep vein thrombosis, or DVT, occurs when a blood clot forms in veins deep within the body, usually in the legs. If left ...